case_images: PMC3628261_01
case_images: The single photon emission tomography-computed tomography (SPECT-CT) scan shows iodine-concentrating lesion in left gluteal muscle
case_images: IJNM-27-38-g001.jpg
case_images: PMC3628261_01_IJNM-27-38-g001.jpg
case_images: F1
case_images: During the follow-up, prompted by elevated thyroglobulin levels, an iodine-131 whole body scan and single photon emission tomography-computed tomography (SPECT-CT) [Figure 1] showed positive lesions, one in the liver and another in the left gluteal region.
case_images: Left gluteal lesions were metabolically active in pretherapy positron emission tomography-computed tomography (PET-CT) study
case_images: IJNM-27-38-g002.jpg
case_images: PMC3628261_01_IJNM-27-38-g002.jpg
case_images: F2
case_images: A fludeoxyglucose (FDG) PET-CT scan [Figure 2] was done to find more lesions and revealed metabolically active lesions in liver segment VI [Figure 3] and the left gluteus and a new paraspinal muscle lesion at the nape of the neck [Figure 4], whereas the lung nodules were metabolically inactive [Figure 5].
case_images: The liver
case_images: IJNM-27-38-g003.jpg
case_images: PMC3628261_01_IJNM-27-38-g003.jpg
case_images: F3
case_images: A fludeoxyglucose (FDG) PET-CT scan [Figure 2] was done to find more lesions and revealed metabolically active lesions in liver segment VI [Figure 3] and the left gluteus and a new paraspinal muscle lesion at the nape of the neck [Figure 4], whereas the lung nodules were metabolically inactive [Figure 5].
case_images: The new lesion at nape of neck
case_images: IJNM-27-38-g004.jpg
case_images: PMC3628261_01_IJNM-27-38-g004.jpg
case_images: F4
case_images: A fludeoxyglucose (FDG) PET-CT scan [Figure 2] was done to find more lesions and revealed metabolically active lesions in liver segment VI [Figure 3] and the left gluteus and a new paraspinal muscle lesion at the nape of the neck [Figure 4], whereas the lung nodules were metabolically inactive [Figure 5].
case_images: Fludeoxyglucose (FDG) activity but not lung nodules
case_images: IJNM-27-38-g005.jpg
case_images: PMC3628261_01_IJNM-27-38-g005.jpg
case_images: F5
case_images: A fludeoxyglucose (FDG) PET-CT scan [Figure 2] was done to find more lesions and revealed metabolically active lesions in liver segment VI [Figure 3] and the left gluteus and a new paraspinal muscle lesion at the nape of the neck [Figure 4], whereas the lung nodules were metabolically inactive [Figure 5].
case_images: The 200 mci post-therapy scan
case_images: IJNM-27-38-g006.jpg
case_images: PMC3628261_01_IJNM-27-38-g006.jpg
case_images: F6
case_images: A post-therapy scan [Figure 6] at a therapeutic dose of 200 mci of iodine-131 revealed iodine concentration in the liver and a gluteal lesion, whereas there was no concentration in lung nodules and neck lesion.
case_images: Concentration in liver and gluteal lesion but no concentration in neck lesion and lung nodules. The positron emission tomography-computed tomography (PET-CT) scan after six months
case_images: IJNM-27-38-g007.jpg
case_images: PMC3628261_01_IJNM-27-38-g007.jpg
case_images: F7
case_images: PET CT scan [Figure 7] as a response evaluation six month post treatment revealed a metabolic response in the liver and gluteal lesion [Figure 8], but an increasing size of the neck lesion [Figure 9] and lung nodules [Figure 10]. Presently, the patient is put on redifferentiation therapy with sorafenib and suppressive doses of thyroxin.
case_images: Iodine therapy shows treatment response in liver
case_images: IJNM-27-38-g008.jpg
case_images: PMC3628261_01_IJNM-27-38-g008.jpg
case_images: F8
case_images: PET CT scan [Figure 7] as a response evaluation six month post treatment revealed a metabolic response in the liver and gluteal lesion [Figure 8], but an increasing size of the neck lesion [Figure 9] and lung nodules [Figure 10]. Presently, the patient is put on redifferentiation therapy with sorafenib and suppressive doses of thyroxin.
case_images: Soft tissue deposit in the neck demonstrating increase in size and FDG uptake (Disease Progression)
case_images: IJNM-27-38-g009.jpg
case_images: PMC3628261_01_IJNM-27-38-g009.jpg
case_images: F9
case_images: PET CT scan [Figure 7] as a response evaluation six month post treatment revealed a metabolic response in the liver and gluteal lesion [Figure 8], but an increasing size of the neck lesion [Figure 9] and lung nodules [Figure 10]. Presently, the patient is put on redifferentiation therapy with sorafenib and suppressive doses of thyroxin.
case_images: Lung nodules
case_images: IJNM-27-38-g010.jpg
case_images: PMC3628261_01_IJNM-27-38-g010.jpg
case_images: F10
case_images: PET CT scan [Figure 7] as a response evaluation six month post treatment revealed a metabolic response in the liver and gluteal lesion [Figure 8], but an increasing size of the neck lesion [Figure 9] and lung nodules [Figure 10]. Presently, the patient is put on redifferentiation therapy with sorafenib and suppressive doses of thyroxin.